Apr 16, 2014 at 09:16 | Source: Moneycontrol.com
Glenmark Generic Inc, USA a subsidiary of Glenmark Generic Limited, has been granted final abbreviated new drug approval (ANDA) from USFDA for Eszopiclone Tablets. Glenmark will commence distribution of the product immediately.
Apr 15, 2014 at 17:51 | Source: CNBC-TV18
The pharma company had licensed out the drug, GBR 500, to Sanofi and had received an upfront payment of USD 50 million dollars from the French drugmaker in 2012.
Apr 15, 2014 at 16:40 | Source: Reuters
The confidence in India marks a shift from last year when IT outsourcing firms and drug makers featured among top gainers as investors sought more exposure to the global economy, with economic growth at its weakest pace in a decade.
Apr 15, 2014 at 14:16 | Source: Reuters
The Suprax recall is the second for India's fourth-largest drugmaker by sales, after pulling nearly 65,000 bottles from the US in January last year because of discoloration.
Apr 09, 2014 at 19:20 | Source: Reuters
Uday Baldota, Sun Pharma's senior vice president of finance and accounts, didn't comment directly when asked whether Sun Pharma will phase out Ranbaxy-branded products in the United States. "Overall Ranbaxy brand has a value," he said. "We will find ways of using it and preserving it."
Apr 09, 2014 at 16:40 | Source: PTI
Lupin said its US subsidiary, Lupin Pharmaceuticals Inc has received final approval for its Pioglitazone tablets from the US Food and Drugs Administration to market generic version of Takeda Pharmaceuticals USA Inc's Actos tablets.
Apr 09, 2014 at 14:20 | Source: Moneycontrol.com
Lupin announced today that it has received final approval for its Pioglitazone Tablets USP, 15 mg, 30 mg, and 45 mg from the United States Food and Drugs Administration (FDA) to market a generic version of Takeda Pharmaceuticals USA, Inc.s (Takeda) Actos Tablets, 15 mg, 30 mg, and 45 mg.
Apr 09, 2014 at 09:53 | Source: Moneycontrol.com
Neuland Laboratories opened a new manufacturing facility constructed as part of its collaboration with Tokyo-based API Corporation (APIC), a healthcare unit of Mitsubishi Chemical Holdings Group that produces APIs, intermediates and investigational new drugs, along with fine chemicals and reagents.
Apr 07, 2014 at 11:21 | Source: Reuters
Daiichi Sankyo said Ranbaxy shareholders will get 0.8 Sun Pharma shares for each Ranbaxy share. The merged company will also become the largest drug firm in India.
Apr 07, 2014 at 09:15 | Source: Moneycontrol.com
Both Sun Pharmaceutical Industries and Ranbaxy are in focus on the back of the acquisition. Sun Pharma will acquire Ranbaxy Laboratories, which has been facing quality issues for its drugs in the US market, in an all-stock transaction with a total value of USD 4 billion.